Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30014709HIVENSG00000065613.15protein_codingSLKNoNo9748Q9H2G2
TVIS30014070HIVENSG00000065613.15protein_codingSLKNoNo9748Q9H2G2
TVIS30001798HIVENSG00000065613.15protein_codingSLKNoNo9748Q9H2G2
TVIS30005689HIVENSG00000065613.15protein_codingSLKNoNo9748Q9H2G2
TVIS30005690HIVENSG00000065613.15protein_codingSLKNoNo9748Q9H2G2
TVIS30011473HIVENSG00000065613.15protein_codingSLKNoNo9748Q9H2G2
TVIS30011474HIVENSG00000065613.15protein_codingSLKNoNo9748Q9H2G2
TVIS30077534HIVENSG00000065613.15protein_codingSLKNoNo9748Q9H2G2
TVIS30075921HIVENSG00000065613.15protein_codingSLKNoNo9748Q9H2G2
TVIS30028532HIVENSG00000065613.15protein_codingSLKNoNo9748Q9H2G2
TCGA Plot Options
Drug Information
GeneSLK
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0004041
UniProt IDQ9H2G2
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830